Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

NCT01284062 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

BIOLOGICAL: Anrukinzumab
BIOLOGICAL: Anrukinzumab
BIOLOGICAL: Anrukinzumab
OTHER: placebo

Sponsor

Pfizer